Drugs / Dendritic Cells (DC)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01278940 | Mar 2002 → Feb 2006 | melanoma | Oslo University Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dendritic Cells (DC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01278940 ↗ |
| Known as | DC-vaccine | “We conclude that immuno-gene-therapy with the described DC-vaccine is feasible and safe, and that the vaccine can elicit in vivo T-cell responses against antigens encoded by...” PMID 16710345 ↗ May 2006 |
| Modality | Vaccine | “We have developed an individualized melanoma vaccine based on transfection of autologous dendritic cells (DCs) with autologous tumor-mRNA.” PMID 16710345 ↗ May 2006 |